Home » Topics » Regulatory » EMA

EMA
RSS

Revlimid receives positive CHMP opinion for myelodysplastic syndrome

April 29, 2013

Authorities expand European approval of Berinert in HAE

April 17, 2013

EMA extends review of Scenesse MAA for erythropoietic protoporphyria

April 8, 2013

EMA accepts ospemifene MAA

March 28, 2013

European CHMP recommends restriction on use of cilostazol-based medicines

March 26, 2013

CHMP recommends against E.U. approval of Gentium's defibrotide

March 26, 2013

CHMP recommends approval of rivaroxaban in new indication

March 26, 2013

FDA and EMA set to review Piramal Imaging's marketing applications

March 26, 2013

CHMP recommends European approval of Biogen Idec's Tecfidera

March 25, 2013

EMA committee recommends approval of ponatinib for two cancer indications

March 25, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...